



NCI-FREDERICK
INSTITUTIONAL BIOSAFETY COMMITTEE

Minutes
July 21, 2009
NCI-Frederick

INTRODUCTION

The NCI-Frederick Institutional Biosafety Committee was convened at 12:04 p.m. in the Building 549 Executive Board Room with the following members in attendance:

Dr. Randall Morin, Chair; Ms. Theresa Bell, IBC Secretary and Biosafety Officer; Dr. Stephen Creekmore; Dr. David Garfinkel; Dr. Serguei Kozlov; Ms. Dianna Conrad; Dr. Bruce Crise; Dr. Eric Freed; Mr. Lucien Winegar; Ms. Alberta Peugeot; Dr. Stephen Hughes; Dr. Dan McVicar; Dr. Melinda Hollingshead.

Members not in attendance: Dr. David Derse; Mr. Scott Jendrek; Dr. Michael Baseler; Dr. Henry Hearn; Reverend David Betzner.

Others in attendance: Dr. Robert Thomas

MINUTES

June 2009 minutes will be distributed for review and approval through email.

REVIEW OF PROTOCOLS

NEW IBC REGISTRATIONS

09-33 (Dr. Ruscetti) *In vivo studies in mice to test the role of the receptor tyrosine kinase sf-RON in tumorigenesis and metastasis.*

- Responses to B5f, B5b and B5c need to be revised.
- Given the hazards associated with these animals, MI caging is not a requirement.
- The registration states that tumors will be passaged orthotopically but does not describe the implantation sites for orthotopic studies – it implies the tumors will be implanted into the organs of origin so will you be doing intraprostate, intrapancreatic, intraovarian implants. Is this correct? If so, the need for additional precautions during injection of the transfected cell lines should be described since these surgeries are not possible with the mice in a restraining device and the mice will require anesthesia.

Dr. Garfinkel made a motion to approved pending resolution of the above issues, Dr. Hollingshead seconded and all were in favor.

09-34 (Dr. Monks) Manipulation of potential drug-target genes with recombinant DNA technology and 09-35 (Dr. Monks) Use of lentiviral based delivery system to express shRNA.

-In A3, expand on the broad classification by providing a list of the types of genes or gene categories (i.e. human, mouse, disease-causing, causing cell transformation, etc). Specify if oncogenes will be used.

-The point was made that this group's function is driven by DTP and so at this point in time, most of the genes to be manipulated are not known. The genes/target agents will be known prior to the lab receiving them and so, an amendment to the IBC at that time would be appropriate.

-How will the work in both registrations be kept separate (temporally and physically)?

-Will all 60 cell lines be used or will just a few be selected?

Dr. Hughes made a motion to approve with clarifications, Dr. Crise seconded and all were in favor.

09-37 (Dr. Marshall) Stable expression of human ErbB2 in brain metastatic MDA-MB-231-BR human breast cancer cells.

-Additional information was requested regarding the injection protocols, which can be obtained from reviewing the ASP document.

-Information regarding who will be responsible for performing the injections was also requested to verify proficiency and training, again, information provided by the ACUC ASP.

Dr. Kozlov made a motion to approve, Dr. Creekmore seconded and all were in favor.

RENEWALS

09-36 (Dr. Hollingshead) In vitro and in vivo drug development.

Dr. Kozlov made a motion to approve this renewal document with no further changes, Dr. Crise seconded and all were in favor.

AMENDMENTS

07-59 (Kinders)

Dr. Crise made a motion to approve, Dr. Kozlov seconded and all were in favor.

08-80 (Giaccone)

Dr. McVicar requested that human pathogen screening results be provided for this additional cell line and approved this amendment as the lead reviewer.

07-10 (Cuttitta)

Dr. Kozlov requested that when renewing this IBC registration to renew two independent registration document, one to address breeding and the other to address work with human cell lines. Dr. Kozlov approved this amendment as the lead reviewer.

06-101 (Pinto) – Dr. Crise made a comment that Troy Kemp did an outstanding job working on the revisions to this IBC and the registration amendment request has been approved.

OUTSTANDING ITEMS

09-23 (Dr. Anver)

-Drs. McVicar and Kozlov have reviewed the revised PHL registration for the receipt of animal specimens and have approved this registration. The draft form for PHL receipt of human material has also been reviewed and approved. The PHL IBC registration addressing the receipt of human specimens should be received for review and approval in the next few weeks.

OTHER BUSINESS

BBP Compliance: 95%

OHS Accident Update:

2 needlesticks were reported by Ms. Sarah Hooper, OHS.

Human Pathogen Screen Update:

-The human pathogen screening should transition from AHDL to MGD sometime early Fall 2009. Updates will be forthcoming.

Acknowledgement of Risk Statement

-This document will be used for all new IBC registrations in which a vaccination may be required to perform the work.

The meeting was adjourned at 1:10 p.m.

Theresa D. Bell, MPH, CBSP
IBC Secretary
Biological Safety Officer, EHS

Date

APPROVED:

Randall S. Morin, Dr. P.H.
Chairman, NCI-Frederick IBC
Director, EHS

Date

xc: Dr. Reynolds
Mr. Wheatley
Dr. Arthur
Mr. Bufter